Abeona Q1 net loss $12M; ZEVASKYN approved Apr 28, PRV sold for $155M

ABEONA THERAPEUTICS INC.

2025-Q1 EPS reported -$0.24

Net loss of $12.0M ($0.24/share) vs. $31.6M ($1.16/share) in Q1 2024; no revenue yet.
FDA approved ZEVASKYN on Apr 28; first QTC (Lurie Children’s) activated, first patient expected Q3 2025.
Entered asset purchase agreement to sell rare pediatric disease PRV for gross proceeds of $155M.
Cash and investments $84.5M at Mar 31, 2025; PRV proceeds to extend runway into early 2026.
~30 patients registered in Abeona Assist; value-based agreements with payers covering ~100M lives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.